Levobupivacaine
As of the edition of 20 October 2026, Levobupivacaine is a small molecule: marketed, first approved in 1999 (US); acts on SCN4A; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Chirocaine
- First approved
- 5 August 1999 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Maruishi Pharmaceutical Co., Ltd.; 2 holders in all
- Registered trials
- 97, 9 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Injuries; Cancer; Heart and blood vessels; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SCN4A | Sodium channel protein type 4 subunit alpha | P35499 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 29 | 18 | 3 | 2 |
| Phase 1 | 3 | 1 | 0 | 0 |
| Phase 2 | 5 | 4 | 0 | 1 |
| Phase 3 | 16 | 10 | 1 | 2 |
| Phase 4 | 44 | 27 | 3 | 4 |
| All trials | 97 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Purdue Pharma | Applicant | 1999 to now |